Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: An expert panel opinion from the American Society for Transplantation and Cellular Therapy Guidelines

  

Authors:	Jain, T.; Bar, M.; Kansagra, A. J.; Chong, E. A.; Hashmi, S. K.; Neelapu, S. S.; Byrne, M.; Jacoby, E.; Lazaryan, A.; Jacobson, C. A.; Ansell, S. M.; Awan, F. T.; Burns, L.; Bachanova, V.; Bollard, C. M.; Carpenter, P. A.; DiPersio, J. F.; Hamadani, M.; Heslop, H. E.; Hill, J. A.; Komanduri, K. V.; Kovitz, C. A.; Lazarus, H. M.; Serrette, J. M.; Mohty, M.; Miklos, D.; Nagler, A.; Pavletic, S. Z.; Savani, B. N.; Schuster, S. J.; Kharfan-Dabaja, M. A.; Perales, M. A.; Lin, Y.
Title:	Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: An expert panel opinion from the American Society for Transplantation and Cellular Therapy
Abstract:	Axicabtagene ciloleucel (YESCARTA; Kite Pharma, a Gilead Company, Los Angeles CA) and tisagenlecleucel (KYM-RIAH; Novartis Pharmaceuticals Corp., Basel, Switzerland) are two CD19-directed chimeric antigen receptor (CAR) T cell products currently approved by the US Food and Drug Administration; the European Medicines Agency; Health Canada; Ministry of Health, Labor and Welfare (Japan); and Therapeutic Goods Administration (Australia) for treatment of specific subtypes of relapsed refractory aggressive B cell non-Hodgkin lymphoma (NHL). Although this approval has been transformative in the use of cellular immunotherapy in lymphoma, there are concerns regarding appropriate use of this novel therapy and of short- and long-term toxicities. To address these issues, representatives of the American Society of Transplantation and Cellular Therapy convened to recognize and address key issues surrounding the clinical application of CD19 CART cell therapy in B cell lymphomas, in collaboration with worldwide experts. The aim of this article is to provide consensus opinion from experts in the fields of hematopoietic cell transplantation, cellular immunotherapy, and lymphoma regarding key clinical questions pertinent to the use of CD19 CART cell products for the treatment of NHL. As the clinical practice using CAR T cells grows worldwide, we anticipate that this guidance will be relevant for hematology/oncology physicians who care for patients with lymphomas. (C) 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.
Keywords:	chemotherapy; neurotoxicity; bendamustine; immunotherapy; humoral immunity; non-hodgkin lymphoma; maintenance; malignancies; diffuse large b cell lymphoma; ibrutinib; salvage regimens; tisagenlecleucel; chimeric antigen receptor t cell therapy
Journal Title:	Biology of Blood and Marrow Transplantation
Volume:	25
Issue:	12
ISSN:	1083-8791
Publisher:	Elsevier Inc.
Date Published:	2019-12-01
Start Page:	2305
End Page:	2321
Language:	English
ACCESSION:	WOS:000505855900001
DOI:	10.1016/j.bbmt.2019.08.015
PROVIDER:	wos
PUBMED:	31446199
Notes:	Article -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/160338